Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
Prostate cancer is a malignant tumor caused by the malignant proliferation of epithelial cells, which is highly heterogeneous and drug-resistant, and neuroendocrine prostate cancer (NEPC) is an essential cause of drug resistance in its late stage. Elucidating the evolution of NEPC and the resistance...
Saved in:
| Main Authors: | Zhe Zhu, Wenjing Xuan, Chaohui Wang, Chancan Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1481777/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Integrated bioinformatics analysis reveals that OPRK1 inhibits ferroptosis and induces enzalutamide resistance in prostate cancer
by: Liangrong Zhang, et al.
Published: (2025-04-01) -
Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer
by: Fu-Hao Ji, et al.
Published: (2025-08-01) -
Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
by: Saizo Fujmoto, et al.
Published: (2023-02-01) -
Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-01-01) -
Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel
by: Hakan Taban, et al.
Published: (2025-06-01)